Baseline characteristics
| . | Overall population . | Matched-pair cohort . | ||
|---|---|---|---|---|
| Haplo (n = 660) . | MMUD (n = 195) . | Haplo (n = 327) . | MMUD (n = 195) . | |
| Recipient age, median (Q1-Q3), y | 52 (37-61) | 56 (44-65) | 55 (41-62) | 56 (44-65) |
| Recipient age, n (%) | ||||
| <50 years | 315 (47.7) | 72 (36.9) | 131 (40.1) | 72 (36.9) |
| ≥50 years | 345 (52.3) | 123 (63.1) | 196 (59.9) | 123 (63.1) |
| Donor age, median (Q1-Q3), y | 34 (24.8-43) | 33 (26-41.5) | 33 (24-43) | 33 (26-41.5) |
| Donor age, y, n (%) | ||||
| <30 years | 271 (41.1) | 83 (43.7) | 142 (43.4) | 83 (43.7) |
| ≥30 years | 389 (58.9) | 107 (56.3) | 185 (56.6) | 107 (56.3) |
| Disease, n (%) | ||||
| AML/MDS | 385 (58.3) | 119 (61.0) | 176 (53.8) | 119 (61.0) |
| ALL | 99 (15.0) | 14 (7.2) | 38 (11.6) | 14 (7.2) |
| Other∗ | 176 (26.7) | 62 (31.8) | 113 (34.6) | 62 (31.8) |
| Disease stage, n (%) | ||||
| Low | 50 (7.6) | 21 (10.8) | 33 (10.1) | 21 (10.8) |
| Intermediate | 372 (56.4) | 107 (54.9) | 200 (61.2) | 107 (54.9) |
| High | 197 (29.8) | 47 (24.1) | 77 (23.5) | 47 (24.1) |
| Very high | 32 (4.8) | 10 (5.1) | 8 (2.4) | 10 (5.1) |
| Missing | 9 (1.4) | 10 (5.1) | 9 (2.8) | 10 (5.1) |
| Conditioning intensity, n (%) | ||||
| MAC | 410 (62.1) | 140 (71.8) | 217 (66.4) | 140 (71.8) |
| RIC/NMA | 250 (37.9) | 55 (28.2) | 110 (33.6) | 55 (28.2) |
| Graft type, n (%) | ||||
| Bone marrow | 466 (70.6) | 71 (36.4) | 142 (43.4) | 71 (36.4) |
| Peripheral blood | 194 (29.4) | 124 (63.6) | 185 (56.6) | 124 (63.6) |
| HCT-CI, n (%) | ||||
| 0 | 120 (18.2) | 42 (21.5) | 66 (20.2) | 42 (21.5) |
| 1-2 | 191 (28.9) | 49 (25.1) | 80 (24.5) | 49 (25.1) |
| ≥3 | 349 (52.9) | 104 (53.3) | 181 (55.4) | 104 (53.3) |
| D/R CMV, n (%) | ||||
| Neg/Neg | 84 (12.8) | 32 (16.5) | 57 (17.4) | 32 (16.4) |
| Neg/Pos | 196 (29.9) | 72 (37.1) | 92 (28.1) | 72 (36.9) |
| Pos/Neg | 52 (7.9) | 25 (12.9) | 27 (8.3) | 25 (12.8) |
| Pos/Pos | 324 (49.4) | 65 (33.5) | 151 (46.2) | 66 (33.8) |
| D/R sex, n (%) | ||||
| Female to male | 138 (20.9) | 41 (21.2) | 63 (19.3) | 41 (21.0) |
| Not female to male | 522 (79.1) | 152 (78.8) | 264 (80.7) | 154 (79.0) |
| KPS, n (%) | ||||
| <90 | 226 (34.2) | 84 (43.1) | 117 (35.8) | 84 (43.1) |
| ≥90 | 323 (48.9) | 88 (45.1) | 157 (48.0) | 88 (45.1) |
| Missing | 111 (16.8) | 23 (11.8) | 53 (16.2) | 23 (11.8) |
| Race, n (%) | ||||
| White | 358 (54.2) | 140 (71.8) | 192 (58.7) | 140 (71.8) |
| Others | 294 (44.5) | 53 (27.2) | 132 (40.4) | 53 (27.2) |
| Missing | 8 (1.2) | 2 (1.0) | 3 (0.9) | 2 (1.0) |
| Time to HCT, n (%) | ||||
| <6 months | 180 (27.4) | 45 (23.1) | 73 (22.3) | 45 (23.1) |
| 6-12 months | 165 (25.1) | 61 (31.3) | 94 (28.7) | 61 (31.3) |
| >12 months | 313 (47.6) | 89 (45.6) | 160 (48.9) | 89 (45.6) |
| Year of HCT, n (%) | ||||
| <2019 | 324 (49.1) | 69 (35.4) | 121 (37.0) | 69 (35.4) |
| ≥2019 | 336 (50.9) | 126 (64.6) | 206 (63.0) | 126 (64.6) |
| Follow-up, median (Q1-Q3), mo† | 54.20 (30.32-84.79) | 25.26 (13.60-62.29) | 49.9 (29.40-76.58) | 25.26 (13.60-62.29) |
| . | Overall population . | Matched-pair cohort . | ||
|---|---|---|---|---|
| Haplo (n = 660) . | MMUD (n = 195) . | Haplo (n = 327) . | MMUD (n = 195) . | |
| Recipient age, median (Q1-Q3), y | 52 (37-61) | 56 (44-65) | 55 (41-62) | 56 (44-65) |
| Recipient age, n (%) | ||||
| <50 years | 315 (47.7) | 72 (36.9) | 131 (40.1) | 72 (36.9) |
| ≥50 years | 345 (52.3) | 123 (63.1) | 196 (59.9) | 123 (63.1) |
| Donor age, median (Q1-Q3), y | 34 (24.8-43) | 33 (26-41.5) | 33 (24-43) | 33 (26-41.5) |
| Donor age, y, n (%) | ||||
| <30 years | 271 (41.1) | 83 (43.7) | 142 (43.4) | 83 (43.7) |
| ≥30 years | 389 (58.9) | 107 (56.3) | 185 (56.6) | 107 (56.3) |
| Disease, n (%) | ||||
| AML/MDS | 385 (58.3) | 119 (61.0) | 176 (53.8) | 119 (61.0) |
| ALL | 99 (15.0) | 14 (7.2) | 38 (11.6) | 14 (7.2) |
| Other∗ | 176 (26.7) | 62 (31.8) | 113 (34.6) | 62 (31.8) |
| Disease stage, n (%) | ||||
| Low | 50 (7.6) | 21 (10.8) | 33 (10.1) | 21 (10.8) |
| Intermediate | 372 (56.4) | 107 (54.9) | 200 (61.2) | 107 (54.9) |
| High | 197 (29.8) | 47 (24.1) | 77 (23.5) | 47 (24.1) |
| Very high | 32 (4.8) | 10 (5.1) | 8 (2.4) | 10 (5.1) |
| Missing | 9 (1.4) | 10 (5.1) | 9 (2.8) | 10 (5.1) |
| Conditioning intensity, n (%) | ||||
| MAC | 410 (62.1) | 140 (71.8) | 217 (66.4) | 140 (71.8) |
| RIC/NMA | 250 (37.9) | 55 (28.2) | 110 (33.6) | 55 (28.2) |
| Graft type, n (%) | ||||
| Bone marrow | 466 (70.6) | 71 (36.4) | 142 (43.4) | 71 (36.4) |
| Peripheral blood | 194 (29.4) | 124 (63.6) | 185 (56.6) | 124 (63.6) |
| HCT-CI, n (%) | ||||
| 0 | 120 (18.2) | 42 (21.5) | 66 (20.2) | 42 (21.5) |
| 1-2 | 191 (28.9) | 49 (25.1) | 80 (24.5) | 49 (25.1) |
| ≥3 | 349 (52.9) | 104 (53.3) | 181 (55.4) | 104 (53.3) |
| D/R CMV, n (%) | ||||
| Neg/Neg | 84 (12.8) | 32 (16.5) | 57 (17.4) | 32 (16.4) |
| Neg/Pos | 196 (29.9) | 72 (37.1) | 92 (28.1) | 72 (36.9) |
| Pos/Neg | 52 (7.9) | 25 (12.9) | 27 (8.3) | 25 (12.8) |
| Pos/Pos | 324 (49.4) | 65 (33.5) | 151 (46.2) | 66 (33.8) |
| D/R sex, n (%) | ||||
| Female to male | 138 (20.9) | 41 (21.2) | 63 (19.3) | 41 (21.0) |
| Not female to male | 522 (79.1) | 152 (78.8) | 264 (80.7) | 154 (79.0) |
| KPS, n (%) | ||||
| <90 | 226 (34.2) | 84 (43.1) | 117 (35.8) | 84 (43.1) |
| ≥90 | 323 (48.9) | 88 (45.1) | 157 (48.0) | 88 (45.1) |
| Missing | 111 (16.8) | 23 (11.8) | 53 (16.2) | 23 (11.8) |
| Race, n (%) | ||||
| White | 358 (54.2) | 140 (71.8) | 192 (58.7) | 140 (71.8) |
| Others | 294 (44.5) | 53 (27.2) | 132 (40.4) | 53 (27.2) |
| Missing | 8 (1.2) | 2 (1.0) | 3 (0.9) | 2 (1.0) |
| Time to HCT, n (%) | ||||
| <6 months | 180 (27.4) | 45 (23.1) | 73 (22.3) | 45 (23.1) |
| 6-12 months | 165 (25.1) | 61 (31.3) | 94 (28.7) | 61 (31.3) |
| >12 months | 313 (47.6) | 89 (45.6) | 160 (48.9) | 89 (45.6) |
| Year of HCT, n (%) | ||||
| <2019 | 324 (49.1) | 69 (35.4) | 121 (37.0) | 69 (35.4) |
| ≥2019 | 336 (50.9) | 126 (64.6) | 206 (63.0) | 126 (64.6) |
| Follow-up, median (Q1-Q3), mo† | 54.20 (30.32-84.79) | 25.26 (13.60-62.29) | 49.9 (29.40-76.58) | 25.26 (13.60-62.29) |
ALL, acute lymphoblastic leukemia; D/R, donor/recipient; Haplo, haploidentical; KPS, Karnofsky performance status; MAC, myeloablative conditioning; Neg, negative; NMA, nonmyeloablative conditioning; Pos, positive; Q1, first quartile; Q3, third quartile; RIC, reduced-intensity conditioning.
Other: chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, other hematologic malignancies.
Follow-up was calculated using the inverse Kaplan-Meier method.